SureTrader Nadex Advertisement Interactive Brokers Advertisement SureTrader
Home > Boards > US Listed > Biotechs >

Organovo Holdings, Inc. (ONVO)

ONVO RSS Feed
Add ONVO Price Alert      Hide Sticky   Hide Intro
Moderator: Dadx4
Search This Board: 
Last Post: 5/21/2017 5:53:40 AM - Followers: 320 - Board type: Free - Posts Today: 0

WELCOME TO THE ORGANOVO BOARD


 
     Organovo is a three-dimensional biology company focused on delivering breakthrough bioprinting technology and creating tissue on demand for research and medical applications.
The company's NovoGen three-dimensional bioprinting technology is a platform that works across all tissue and cell types.
Organovo's NovoGen MMX Bioprinter was selected as one of the "Best Inventions of 2010" by TIME Magazine.
Organovo is helping pharmaceutical partners develop human biological disease models in three dimensions that enable therapeutic drug discovery and development.
Organovo's bioprinting technology can also be developed to create surgical tissues direct therapy.
Organovo leads the way in solving complex medical research problems and building the future of medicine.

COMPANY PROFILE via YouTube
http://www.youtube.com/watch?feature=player_embedded&v=-A-uH15bQZw

 
ONVO Security Details Share Structure

Shares Outstanding 77,816,787 a/o Mar 16, 2014
Float 50,000,000 a/0 May24,2014
Authorized Shares 150,000,000 a/o May24, 2014


IR and Media Contacts:
Investor Relations Contact: ir@organovo.com
Media Contact: media@organovo.com

Mailing Address:
Organovo, Inc.
6275 Nancy Ridge Drive, Suite 110
San Diego, CA 92121
Phone: 1-858-550-9994


For all the latest company information, details, news, please visit http://www.organovo.com

 
Organovo's Scientific Founder and Chief Scientific Officer, Dr. Gabor Forgacs
is the Executive and Scientific Director of the Shipley Center for Innovation at Clarkson University and the George H. Vineyard Professor of Biological Physics at the University of Missouri.
He developed Organovo's breakthrough organ printing technology while leading a team of top regenerative medicine scientists from multiple universities, with the backing of a $5MM National Science Foundation Grant.
Professor Forgacs is the author of more than 150 peer reviewed journal articles and the textbook Biological Physics of the Developing Embryo, (with Stuart Newman), published by Cambridge University Press.
He holds a PhD in theoretical physics from the Roland Eotvos University, Budapest Hungary. He moved to the United States in the 1980's from the Institute of Physics of the French Atomic Energy Agency in Saclay to accept a professorship at Clarkson University. 
University of Missouri researcher doing groundbreaking work in regenerative medicine. Here is a video:

Science

Organovo strives to advance regenerative medicine to new heights, by enabling bioprinting tissues and 3-D cellular constructs that were not possible before.
The novel and flexible capabilities of the bioprinting technology allow researchers to generate data faster and more efficiently, thus leading to cutting edge scientific findings, publications, and grants.

Organovo's 3-D NovoGen bioprinting technology allows for the placement of cells in any pattern desired.
First, small building blocks of any shape are created from the desired cell type.
Second, these pre-formed cell aggregates are loaded into a print cartridge that is then attached to the bio-printer.
The bioprinter deposits the cell aggregates one layer at a time, creating multiple stacked 2-D patterns.
A non-invasive gel is placed next to the cell aggregates to hold the desired 3-D shape as each layer is placed in 2-D.

After printing, the cell aggregates retain enough cellular mobility for them to flow into one another, creating a fused tissue construct.
The principles of developmental biology, including cellular self-assembly, allow the final construct to mature into the desired shape and properties.

 

World class support for NovoGen MMX

The NovoGen MMX Bioprinter™ is supported by our scientific and engineering team.
Every customer receives bioprinter training and access to Organovo's scaffold-free proprietary bioprinting process, which includes cell preparation to tissue maturation.
Additional consultation and application support are available upon request. Organovo's success comes from enabling our customers' success.  

 

NovoGen MMX Bioprinter

    The NovoGen MMX Bioprinter™ is a novel hardware and software platform at the forefront of bioprinting research and development. The NovoGen MMX™ was developed to meet challenges in biological research.
The platform takes primary or other human cells and shapes them into 3D tissue, with tremendous cellular viability and biology that is superior to even an animal model.
The platform is being used by Organovo's Pharma partners today to enable cutting edge research into drug discovery.

By allowing creation of three dimensional biological structures, Organovo creates functional human tissue that is superior to current disease models.
By enabling printing of tissue in a laboratory environment, investigations on the constructs can be integrated into your current analysis methods.

http://www.invetech.com.au/portfolio/life-sciences/3d-bioprinter-world-first-print-human-tissue/
http://techli.com/2012/07/organovo-bioprinting/#.
https://www.youtube.com/watch?v=1O3c3pUg0L8 (at 28 sec into the video is a full frontal view of the ONVO NovaGen MMX Bioprinter)

  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
ONVO
Current Price
Volume:
Bid Ask Day's Range
ONVO News: Organovo Presents New Preclinical Data on 3D Bioprinted Human Liver Tissues at World Advanced Therapies and Regenerative Medi... 05/18/2017 08:05:00 AM
ONVO News: Statement of Changes in Beneficial Ownership (4) 05/17/2017 07:10:22 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 05/17/2017 07:09:02 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 05/17/2017 07:07:32 PM
ONVO News: Statement of Changes in Beneficial Ownership (4) 05/17/2017 07:06:24 PM
PostSubject
#9959  Sticky Note Organovo Collaborates With University of Virginia to Develop Dadx4 05/01/17 08:29:13 AM
#9982   I think you might just be right. Management CIMA7 05/21/17 05:53:40 AM
#9981   Took onvo to long. They had such a stuntmanpatch 05/17/17 11:42:40 PM
#9980   Closing above $2.85 was key. We'll see WHP03 05/16/17 04:20:06 PM
#9979   And there it goes... Yer mah favorite deputy. RandolRocketman 05/16/17 04:15:04 PM
#9978   HOD close on the way, Nice call! ONVO$$$$$ jjh573 05/16/17 03:16:24 PM
#9977   We need to get past $2.85 to retest WHP03 05/15/17 07:59:24 PM
#9976   "$630,000.00 in Sales Expected for Organovo Holdings Inc xxxWEEMANxxx 05/15/17 03:50:58 PM
#9975   Very pretty. Not sure I understand all that, RandolRocketman 05/15/17 03:27:23 PM
#9974   I'd say it can do what it recently WHP03 05/15/17 10:41:10 AM
#9973   Even little noises like executives giving charitable donations RandolRocketman 05/14/17 07:17:00 PM
#9972   Nice increase on no news, but always traders Alvie 05/12/17 03:58:50 PM
#9971   Market Capitalization $282.95M RandolRocketman 05/12/17 11:50:10 AM
#9970   Not a great stock for flipping, but a RandolRocketman 05/09/17 08:43:47 PM
#9969   Total Revenue (TTM) RandolRocketman 05/05/17 02:34:55 PM
#9968   What are you doing in these parts pal? thewind 05/04/17 11:13:48 PM
#9967   With all their collaborations, grants, and investor dog miji 05/04/17 10:22:13 PM
#9966   Incredible indeed. Limitless potential phytokaiser1 05/04/17 09:56:13 PM
#9965   Fantastic long play. Short term could be anything. phytokaiser1 05/04/17 09:55:03 PM
#9964   In my opinion this will go to the onesies TOPPA 05/04/17 07:26:35 PM
#9963   Is there a huge Elliot wave in that Magic Money 05/04/17 07:22:20 PM
#9962   3D printed muscle tissue on demand. What hospital RandolRocketman 05/03/17 11:04:39 PM
#9961   If you can do it to a bicep tyfoidhana 05/01/17 12:31:34 PM
#9960   This is very good news. Thousands of morley480 05/01/17 11:10:02 AM
#9959   Organovo Collaborates With University of Virginia to Develop Dadx4 05/01/17 08:29:13 AM
#9958   Market Capitalization $302.79M RandolRocketman 04/30/17 08:53:16 PM
#9957   Long before that would be 3D printers at RandolRocketman 04/30/17 04:29:48 PM
#9956   I didn't mean to imply DDD was in RandolRocketman 04/27/17 02:34:34 PM
#9955   ONVO is not going to deal with DDD. phytokaiser1 04/26/17 10:26:57 PM
#9954   Seems like the market likes this story: 3D RandolRocketman 04/26/17 04:04:24 PM
#9953   I'm with ya there. ONVO has been in RandolRocketman 04/25/17 05:34:53 PM
#9952   I hope so... wouldn't be here if I thewind 04/25/17 04:22:18 PM
#9951   The only thing ONVO is disrupting are the RallyTheMarket 04/25/17 04:04:30 PM
#9950   Well, we'll see. Seems more often that a RandolRocketman 04/25/17 03:58:49 PM
#9949   Starve them and buy them out cheap. thewind 04/25/17 02:05:53 PM
#9948   By the way, if ONVO's TOX testing is RandolRocketman 04/25/17 10:02:55 AM
#9947   There have already been concerted, illegal efforts to RandolRocketman 04/25/17 09:37:06 AM
#9946   Large pharma's need to stifle technology like this thewind 04/24/17 09:57:17 AM
#9945   Seems that way to me to. The WHP03 04/23/17 08:24:05 PM
#9944   Hate to say it, but I think they thewind 04/22/17 12:25:05 PM
#9943   Nicely said.... WHP03 04/20/17 05:53:08 PM
#9942   JOHNSON AND JOHNSON BUYING UP 3D PRINTER TECH. RandolRocketman 04/20/17 04:36:59 PM
#9941   I agree with most of your assessment. We thewind 04/20/17 08:31:31 AM
#9940   $2.48, the low post surprise downround secondary (when WHP03 04/18/17 03:40:55 PM
#9939   selloff continues is 2.25 the floor? chris hedges 04/18/17 10:33:50 AM
#9938   Hopefully he won't, phytokaiser1 04/16/17 12:12:11 PM
#9937   He is still chairman. I would say expanding Samsara... thewind 04/13/17 05:22:27 PM
#9936   I'm watching for a slight dip when Murphy RandolRocketman 04/13/17 11:22:00 AM
#9935   Let's see what it does at 2.75 then thewind 04/12/17 10:15:34 AM
#9934   $ONVO down on CEO move, wheres the base chris hedges 04/12/17 09:53:19 AM
#9933   It was done quickly I'll give them that. RandolRocketman 04/11/17 06:57:15 PM
PostSubject